Pharmaceutical care in the screening process of phase I oncohaematological clinical trials.

Rosa Rodríguez-MaurizMonica González-LagunaMaria Perayre-BadiaToni Lozano-AndreuMaria Emilia Miquel-ZuritaSalomé Cañizares-PazLorena Santulario-VerdúMarina Millan-CollSandra FontanalsAna Clopés-Estela

Published in: European journal of hospital pharmacy : science and practice (2024)

The pharmacist's review of concomitant medication during the screening period in phase I clinical trials enables the detection of prohibited medication or relevant interactions, potentially avoiding screening failures and increasing the efficacy and safety of treatments.

Keyphrases

clinical trial
healthcare
adverse drug
emergency department
randomized controlled trial
phase ii
quality improvement
open label
double blind
electronic health record
loop mediated isothermal amplification
quantum dots
real time pcr